Baseline patient and treatment characteristics of older patients (aged more than 60 years) with DLBCL treated with R-CHOP in The Netherlands according to sex, from 2014 to 2020
| Characteristics . | Male . | Female . | P . | Total . | |||
|---|---|---|---|---|---|---|---|
| N . | (%) . | N . | (%) . | N . | (%) . | ||
| Total no. of patients | 2121 | — | 1660 | — | 3781 | — | |
| Age at diagnosis, y | |||||||
| Median (IQR) | 72 (67-77) | 73 (68-78) | < .001 | 72 (67-77) | |||
| 61-70 | 909 | (43) | 626 | (38) | .001 | 1535 | (41) |
| 71-80 | 940 | (44) | 771 | (46) | 1711 | (45) | |
| >80 | 272 | (13) | 263 | (16) | 535 | (14) | |
| Stage at diagnosis∗ | .241 | ||||||
| I-II | 722 | (34) | 596 | (36) | 1318 | (35) | |
| III-IV | 1388 | (65) | 1057 | (64) | 2445 | (65) | |
| Unknown | 11 | (1) | 7 | (0) | 18 | (0) | |
| LDH > ULN∗ | .117 | ||||||
| No | 994 | (47) | 731 | (44) | 1725 | (46) | |
| Yes | 1093 | (52) | 892 | (54) | 1985 | (52) | |
| Unknown | 34 | (2) | 37 | (2) | 71 | (2) | |
| Extranodal sites | .332 | ||||||
| ≤1 | 1499 | (71) | 1149 | (69) | 2648 | (70) | |
| >1 | 622 | (29) | 511 | (31) | 1133 | (30) | |
| WHO performance score | .346 | ||||||
| 0 | 635 | (30) | 457 | (28) | 1092 | (29) | |
| 1 | 412 | (19) | 357 | (22) | 769 | (20) | |
| 2 | 129 | (6) | 118 | (7) | 247 | (7) | |
| 3 | 53 | (2) | 38 | (2) | 91 | (2) | |
| 4 | 7 | (0) | 6 | (0) | 13 | (0) | |
| Unknown | 878 | (41) | 679 | (41) | 1 557 | (41) | |
| IPI | .803 | ||||||
| Low (0-1) | 302 | (14) | 235 | (14) | 537 | (14) | |
| Low-int (2) | 276 | (13) | 218 | (13) | 494 | (13) | |
| High-int (3) | 337 | (16) | 254 | (15) | 591 | (16) | |
| High (4-5) | 480 | (23) | 403 | (24) | 883 | (23) | |
| Unclassifiable† | 726 | (34) | 550 | (33) | 1276 | (34) | |
| Time from diagnosis to treatment | |||||||
| Median (IQR), d | 24 (15-35) | 24 (15-36) | 0.892 | 24 (15-35) | |||
| 0-13 d | 433 | (20) | 321 | (19) | .708 | 754 | (20) |
| 14-27 d | 826 | (39) | 658 | (40) | 1484 | (39) | |
| ≥28 d | 862 | (41) | 681 | (41) | 1 543 | (41) | |
| Center of treatment | .403 | ||||||
| Nonacademic | 1911 | (90) | 1509 | (91) | 3420 | (90) | |
| Academic | 210 | (10) | 151 | (9) | 361 | (10) | |
| Best response | .184 | ||||||
| Complete remission | 1591 | (75) | 1286 | (77) | 2877 | (76) | |
| Partial remission | 14 | (1) | 9 | (1) | 23 | (1) | |
| Stable disease | 68 | (3) | 36 | (2) | 104 | (3) | |
| Progressive disease | 237 | (11) | 185 | (11) | 422 | (11) | |
| Unknown | 211 | (10) | 144 | (9) | 355 | (9) | |
| Characteristics . | Male . | Female . | P . | Total . | |||
|---|---|---|---|---|---|---|---|
| N . | (%) . | N . | (%) . | N . | (%) . | ||
| Total no. of patients | 2121 | — | 1660 | — | 3781 | — | |
| Age at diagnosis, y | |||||||
| Median (IQR) | 72 (67-77) | 73 (68-78) | < .001 | 72 (67-77) | |||
| 61-70 | 909 | (43) | 626 | (38) | .001 | 1535 | (41) |
| 71-80 | 940 | (44) | 771 | (46) | 1711 | (45) | |
| >80 | 272 | (13) | 263 | (16) | 535 | (14) | |
| Stage at diagnosis∗ | .241 | ||||||
| I-II | 722 | (34) | 596 | (36) | 1318 | (35) | |
| III-IV | 1388 | (65) | 1057 | (64) | 2445 | (65) | |
| Unknown | 11 | (1) | 7 | (0) | 18 | (0) | |
| LDH > ULN∗ | .117 | ||||||
| No | 994 | (47) | 731 | (44) | 1725 | (46) | |
| Yes | 1093 | (52) | 892 | (54) | 1985 | (52) | |
| Unknown | 34 | (2) | 37 | (2) | 71 | (2) | |
| Extranodal sites | .332 | ||||||
| ≤1 | 1499 | (71) | 1149 | (69) | 2648 | (70) | |
| >1 | 622 | (29) | 511 | (31) | 1133 | (30) | |
| WHO performance score | .346 | ||||||
| 0 | 635 | (30) | 457 | (28) | 1092 | (29) | |
| 1 | 412 | (19) | 357 | (22) | 769 | (20) | |
| 2 | 129 | (6) | 118 | (7) | 247 | (7) | |
| 3 | 53 | (2) | 38 | (2) | 91 | (2) | |
| 4 | 7 | (0) | 6 | (0) | 13 | (0) | |
| Unknown | 878 | (41) | 679 | (41) | 1 557 | (41) | |
| IPI | .803 | ||||||
| Low (0-1) | 302 | (14) | 235 | (14) | 537 | (14) | |
| Low-int (2) | 276 | (13) | 218 | (13) | 494 | (13) | |
| High-int (3) | 337 | (16) | 254 | (15) | 591 | (16) | |
| High (4-5) | 480 | (23) | 403 | (24) | 883 | (23) | |
| Unclassifiable† | 726 | (34) | 550 | (33) | 1276 | (34) | |
| Time from diagnosis to treatment | |||||||
| Median (IQR), d | 24 (15-35) | 24 (15-36) | 0.892 | 24 (15-35) | |||
| 0-13 d | 433 | (20) | 321 | (19) | .708 | 754 | (20) |
| 14-27 d | 826 | (39) | 658 | (40) | 1484 | (39) | |
| ≥28 d | 862 | (41) | 681 | (41) | 1 543 | (41) | |
| Center of treatment | .403 | ||||||
| Nonacademic | 1911 | (90) | 1509 | (91) | 3420 | (90) | |
| Academic | 210 | (10) | 151 | (9) | 361 | (10) | |
| Best response | .184 | ||||||
| Complete remission | 1591 | (75) | 1286 | (77) | 2877 | (76) | |
| Partial remission | 14 | (1) | 9 | (1) | 23 | (1) | |
| Stable disease | 68 | (3) | 36 | (2) | 104 | (3) | |
| Progressive disease | 237 | (11) | 185 | (11) | 422 | (11) | |
| Unknown | 211 | (10) | 144 | (9) | 355 | (9) | |